ICU mortality following ICU-acquired primary bloodstream infections according to the type of pathogen: A prospective cohort study in 937 Germany ICUs (2006-2015) by Schwab, Frank et al.
RESEARCH ARTICLE
ICU mortality following ICU-acquired primary
bloodstream infections according to the type
of pathogen: A prospective cohort study in
937 Germany ICUs (2006-2015)
Frank Schwab1,2*, Christine Geffers1,2, Michael Behnke1,2, Petra Gastmeier1,2
1 Charite´ –Universita¨tsmedizin Berlin, corporate member of Freie Universita¨t Berlin, Humboldt-Universita¨t zu
Berlin, and Berlin Institute of Health, Institute for Hygiene and Environmental Medicine, Berlin, Germany,




Mortality due to intensive care unit (ICU) acquired primary blood stream infections (PBSI) is
related primarily to patient co-morbidities, types of pathogens and quality of care. The objec-
tive of this study is to determine the impact of various types of pathogen on ICU mortality.
Methods
Data from the German National Nosocomial Infection Surveillance System of patients with
PBSI from 2006 to 2015 was used for this analysis. A BSI is primary when the pathogen rec-
ognized is not related to an infection on another site. Only mono-microbial infections strati-
fied into the 13 pathogens most frequently causing PBSI were considered. Univariate and
multivariate risk factor analyses were performed using the following risk factors: Sex, age,
length of stay, device use, time until onset of PBSI, type and size of hospital, type of ICU
and type of pathogen. ICU mortality following S.aureus PBSI was used as the reference
value.
Results
A total of 4,556,360 patients with 16,978,882 patient days from 937 ICUs were considered
in the analysis. Of 14,626 PBSI in total, 12,745 mono-microbial PBSI were included. The
ICU mortality was 18.6%. Compared with S.aureus and adjusted by age, sex and type of
ICU, S.maltophilia was associated with significantly higher ICU mortality (OR 1.71; 95%CI
1.19–2.47) as followed by Enterococci (OR 1.20; 95%CI 1.06–1.36), E.coli (OR 1.24; 95%
CI 1.02–1.49), C.albicans (OR 1.37; 95%CI 1.16–1.61), non albicans Candida spp. (OR
1.49; 95%CI 1.18–1.88) and P.aeruginosa (OR 1.49; 95%CI 1.21–1.84). Coagulase nega-
tive Staphylococci were associated with significant lower ICU mortality (OR 0.86; 95%CI
0.75–0.99).
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Conclusion
Because of the limitation of the study in adjusting for severity of illness and appropriateness
of therapy, the differences between the pathogens may not only be explained by differences
in virulence, but may reflect the prognosis after receiving the microbiological results and
may therefore be useful for intensive care physicians.
Introduction
Primary bloodstream infections (PBSI) in intensive care units (ICU) are associated with high
mortality. This mortality is related to patient factors (sex, age and underlying diseases), ade-
quate antibiotic therapy ICU factors (staff to patient ratios, safety climate, etc.) and the patho-
gens responsible. Some pathogens (e.g. P.aeruginosa) and some multi-drug resistant variants
of pathogens (e.g. multiresistant A.baumannii) are known to be associated with significantly
higher ICU mortality [1–3]. However, such information is not available for many other patho-
gens that frequently cause primary bloodstream infections (PBSI).
The reason for this lack of information is the need to analyze large numbers of PBSI cases.
In addition, it would be preferable to diagnose infections by applying definitions designed for
surveillance and not those derived from other databases, e.g. discharge data. Furthermore,
information about the most important risk factors needs to be available, including the time
interval between ICU admission and the onset of infection. Therefore, only a few studies have
been able to provide comparable information about mortality based on the type of pathogen
[3–8]. Many included only a small number of species or did not consider information for such
frequently occurring pathogens like E.coli or Enterococci.
The ICU component of the German National Nosocomial Infection Surveillance System
(KISS) includes a large number of ICUs [9]. In the case of healthcare-associated PBSI, it rec-
ords not only the type of pathogen isolated from relevant microbiological samples, but also the
time from admission to the ICU until occurrence of PBSI. This database allows the analysis of
differences between various pathogens that cause PBSI in ICUs in ICU mortality.
The objective of this study is to determine the impact of the type of pathogen on ICU mor-
tality following a ICU-acquired PBSI.
Material and methods
Ethics statement
All data was anonymous and was collected in accordance with the German recommendations
for good epidemiological practice with respect to data protection ((DAE) AEMdDAE (2013)
Leitlinien und Empfehlungen zur Sicherung von Guter Epidemiologischer Praxis (GEP):
http://www.gesundheitsforschung-bmbf.de/_media/GEP.pdf. Accessed 05 May 2017). A fed-
eral law, the German Protection against Infection Act (Infektionsschutzgesetz §23) regulates
the prevention and management of infectious disease in humans. All hospitals are obliged to
continuously collect and analyse healthcare-associated infections and drug-resistant pathogens
(German Protection against Infection Act. "Gesetz zur Verhu¨tung und Beka¨mpfung von Infek-
tionskrankheiten beim Menschen" (2013): http://www.gesetze-im-internet.de/ifsg/index.html.
Accessed 05 May 2017). This data is reported regularly to the National Reference Centre for
the Surveillance for Nosocomial Infections. Ethical approval and informed consent were,
therefore, not required.
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participating in the system. We are not allowed to
publish unaggregated data which might lead to
identification of individual hospitals directly or
through a third party. Researchers who want to
obtain the data set required to reproduce our
findings are asked to direct their request to: Data
Access Committee Nationales Referenzzentrum
(NRZ) fu¨r Surveillance von nosokomialen
Infektionen am Institut fu¨r Hygiene und
Umweltmedizin Charite´-Universita¨tsmedizin Berlin
(nrz@charite.de).
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Data collection
Surveillance data from a ten-year period from January 2006 until December 2015 was used for
the analysis. ICU-KISS is a unit-based surveillance system like the ICU component of the
American National Healthcare Safety Network (NHSN). During this period, CDC definitions
were used to diagnose PBSI [10]. A primary BSI was defined as a positive blood culture with
one (or more) pathogen(s) which was not related to an infection on another site. For a BSI
with skin germs, for example with coagulase negative Staphylococci (CNS), the definition also
requires further clinical signs and the physician starts according to an antibiotic therapy. How-
ever, beginning in 2011 a new CDC definition of PBSI with skin germs was introduced [11].
Since that time two separate blood cultures are required for skin germs in combination with
other clinical signs. The PBSI was defined as CVC-associated when the patient that had a CVC
at the time of or within 48 hours before onset of the infection.
In the case of an ICU-acquired PBSI, the surveillance staff has to record the time to BSI, the
ICU mortality and the pathogens identified in the blood culture. Up to four pathogens can be
recorded per infection. Only mono-microbial infections were considered in the analysis. The
13 most common organisms causing PBSI were analyzed individually: coagulase negative
Staphylococci (CNS), Enterococcus spp., S.aureus, C.albicans, non-albicans-Candida spp., E.
coli, Klebsiella spp., Enterobacter spp., P.aeruginosa, Serratia spp., Acinetobacter spp., Proteus
spp., and S.maltophilia. All other pathogens were analyzed as type “other”. In addition, for the
13 organisms specified we categorized the organisms into the pathogen groups (gram-posi-
tive/gram-negative bacteria/fungi) and multi-drug resistance groups (non-MDR/MDR). MDR
was defined as Methicillin resistant for S.aureus, Vancomycin resistant for E.faecalis and E.fae-
cium, and a resistance to at least three antibiotic groups for P.aeruginosa, Acinetobacter spp.,
Enterobacter spp., E.coli, S.maltophilia, Klebsiella spp. and/or the resistance mechanisms ESBL
for K.pneumonia and E.coli.
Statistical analysis
In our analysis, the primary outcome was ICU mortality following ICU-acquired PBSI. Uni-
variable and multivariable risk factor analyses were performed to identify organisms (pathogen
groups and/or multidrug resistance groups) associated with increased or decreased risk of ICU
mortality as well as additional related factors and confounders, such as sex (male/female),
age group (45/46-55/56-65/66-75/>75years), time from admission to the ICU until onset
of PBSI(days), CVC associated with PBSI (no/yes), type of ICU (8 categories), size of ICU
(</12 beds), type of hospital (tertiary care yes/no), and size of hospital (</600 beds),
season(Dec-Feb/Mar-May/Jun-Aug/Sep-Nov) and long-term time trends (year). In the uni-
variable analysis, differences were tested by Chi-Square test or Wilcoxon rank-sum test.
Parameters with more than two categories were tested as binary parameters.
In the multivariable analysis, a logistic regression analysis was performed. Since observa-
tions within an ICU are not statistically independent due to varying patient populations (espe-
cially the treatment management), adjusted odds ratios (OR) with 95% confidence intervals
(CI) were calculated. They were based on generalized estimating equation (GEE) models
which account for this clustering effect by using an exchangeable correlation structure. The
multivariable model building strategy was performed stepwise backward, from a full model
with all parameters, non-significant parameters were excluded with the significance level of
p = 0.05 for excluding a parameter from the model in the type III test. S.aureus was used as ref-
erence micro-organisms because this pathogen frequently causes PBSI, and it is very likely
that, when detected in a blood culture, it is the responsible pathogen, in contrast to coagulase
negative Staphylococci, which are often regarded as skin contaminants. In addition, experts
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agree that S.aureus is a common cause of severe bloodstream infections, and mortality and
morbidity of S.aureus bacteremia still remain considerably high [12–13]. Furthermore, other
studies have provided substantial information about S.aureus mortality which can be used for
comparison [8], [14]. For epidemiological reasons, age group and sex were included in all
models. P-values less than 0.05 were considered significant.
Beside age, gender and time to PBSI, no more individual patient-based parameters are
available in the multivariable analysis which describe the severity of illness of the patients.
However, structure parameters, such as type and size of ICU, and type and size of the hospital
where the ICU is located, were considered in the multivariable analysis.
In addition, to better characterize risk potential of patients, we conducted a further multi-
variable analysis which considered the monthly mean of length of stay (LOS), device use (cen-
tral venous catheter, invasive ventilation and urinary tract catheter) and bed occupation of the
ICU in which the PBSI occurs. These results do not differ from the results without these
parameters. Therefore, we present the results without these parameters.
All analyses were performed using SPSS [IBM SPSS statistics, version 23, Somer, NY, USA]
and SAS 9.4 [SAS Institute, Cary, NC, USA].
Results
A total of 4,556,360 patients with 16,978,882 patient days from 937 ICUs (> = 1 PBSI) were
considered in the analysis. Table 1 describes the characteristics of the ICUs included.
A total of 14,626 PBSI were recorded, that is, an incidence of 0.32 per 100 patients or 0.86
per 1000 patient days. 95% of the PBSI were CVC-associated and the proportion does not
change during the study period. For 12,745 PBSI, only one pathogen was isolated from the
blood culture (87.1%).
Table 1. Characteristics of 973 intensive care units (ICU) included in the study, ICU-KISS, 2006–2015.
Parameter Description Number Percentage
ICUs total 937 100.0%
Surveillance time of ICU Months (median, IQR) 56 30–95
Size of ICU ICU beds (median, IQR) 12 8–15
Size of hospital Hospital beds (median, IQR) 439 270–749
Type of hospital Non tertiary care 659 70.4
Tertiary care 278 29.6







Other a 45 4.8%
Length of stay Days (median, IQR) 3.7 2.9–5.3
CVC utilization rate CVC days per 100 pd (median, IQR) 65.9 51.0–79.8
Ventilator utilization rate Ventilator days per 100 pd (median, IQR) 35.5 25.4–49.5
UC utilization rate UC days per 100 pd (median, IQR) 84.0 72.8–91.7
Incidence density PBSI PBSI/1000 pd (median, IQR) 0.64 0.33–1.14
PBSI, primary bloodstream infection; CVC, central venous catheter; UC, urinary catheter; pd, patient days; IQR, interquartile range.
a other than Medical-surgical, Surgical, Medical, Cardiothoracic, Neurosurgical, Neurological or Pediatric.
https://doi.org/10.1371/journal.pone.0194210.t001
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The overall ICU mortality was 18.6% for PBSI. Mortality in multi-microbial PBSI was
24.1% (RR = 1.29, 95%CI 1.17–1.43, p<0.001 compared to mono-microbial PBSI).
Time in the ICU until onset of PBSI was in median 14 days and differs depending on the
type of pathogen, PBSI were observed early in the case of E.coli (11 days) or S.aureus (12 days),
but late if Klebsiella spp., non-albicans Candida spp. (both 16 days), P.aeruginosa (18 days) or
S.maltophilia (19 days) were found.
Table 2 shows mortality following mono-microbial PBSI for the various risk groups, con-
founders and pathogens in ICU-KISS from 2006 to 2015. Significances were found for sex,
age, type of ICU and hospital also for type of organisms, organism groups and multidrug resis-
tance groups responsible.
Table 2. Results of univariate analysis for mortality in intensive care units (ICU) following mono-microbial primary bloodstream infections (PBSI) according to
the type of organism and further risk factors and confounders, ICU-KISS, 2006–2015.
Parameter Category No. not died No. died Mortality (%) p-valuea
Patients with BSI Total 10369 2376 18.6
Type of organism CNS 3579 641 15.2 <0.001
Enterococcus spp. 1636 471 22.4 <0.001
S. aureus 1522 338 18.2 0.573
Candida albicans 510 166 24.6 <0.001
E. coli 434 125 22.4 0.021
Klebsiella spp. 498 102 17.0 0.290
Enterobacter spp. 366 68 15.7 0.105
P. aeruginosa 242 84 25.8 0.001
non-albicans-Candida spp. 172 64 27.1 0.001
Serratia spp. 162 27 14.3 0.121
Acinetobacter spp. 91 21 18.8 0.977
Proteus spp. 72 12 14.3 0.304
S. maltophilia 48 19 28.4 0.041
Other organisms b 1037 238 18.7 0.981
Time to onset of infection Days (median) 14 14 0.958
Gender Male 6989 1541 18.1 0.017
Age Years (median) 68 73 <0.001
Age group 45 years 2563 273 9.6 <0.001
46–55 years 1990 399 16.7 0.007
56–65 years 3010 730 19.5 0.102
>65 years 2806 974 25.8 <0.001
CVC associated g Yes 9846 2276 18.8 0.089
Size of hospital 600 beds 5372 1224 18.6 0.796
Size of ICU 12 beds 7264 1637 18.4 0.267
Type of hospital Tertiary care 4778 968 16.8 <0.001
Type of ICU Interdisciplinary 4668 1098 19.0 0.292
Medical 1437 417 22.5 <0.001
Surgical 2482 525 17.5 0.057
Neurosurgical 360 26 6.7 <0.001
Cardiosurgical 437 157 26.4 <0.001
Neurological 215 23 9.7 <0.001
Pediatric 324 19 5.5 <0.001
Other h 446 111 19.9 0.426
Year of BSI 2006 687 157 18.6 0.426
2007 784 159 16.9 0.975
(Continued)
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ICU mortality following mono-microbial ICU-acquired PBSI for the type of pathogen is
also illustrated in Fig 1 and stratified according to the resistance of pathogen in Fig 2.
Table 3 and Fig 3 show the results of the multivariable analysis for ICU mortality following
PBSI of various pathogens compared to S.aureus. Adjusted by gender, age group and the type
of ICU, Enterococci, E.coli, C.albicans and Non-albicans Candida spp., S. maltophilia and P.
aeruginosa were associated with higher mortality compared to S.aureus; CNS with lower mor-
tality respectively.
Table 4 shows the results of the multivariable analysis for mortality following PBSI stratified
by pathogen groups (gram-positive, gram-negative bacteria and fungi) and table 5 by multi-
drug resistance groups (non-multi-drug resistant/multi-drug resistant).
Discussion
The present study evaluated ICU mortality after PBSI in relation to various types of pathogen
in a large cohort of more than 4.5 Mio ICU patients. PBSI with Enterococci, E.coli, C.albicans
and Non-albicans Candida spp., S. maltophilia and P.aeruginosa were associated with higher
Table 2. (Continued)
Parameter Category No. not died No. died Mortality (%) p-valuea
2008 830 191 18.7 0.956
2009 958 197 17.1 0.147
2010 1000 230 18.7 0.957
2011 1051 225 17.6 0.329
2012 1120 251 18.3 0.736
2013 1230 299 19.6 0.329
2014 1335 318 19.2 0.505
2015 1374 349 20.3 0.065
Season Winter (Dec-Feb) 2396 577 19.4 0.221
Spring (Mar-May) 2613 620 19.2 0.366
Summer (Jun-Aug) 2797 609 17.9 0.182
Autumn (Sep-Nov) 2563 570 18.2 0.457
Pathogen groups Gram-positive d 6737 1450 17.7 <0.001
(N = 11470) Gram-negative e 1913 458 19.3 0.342
Fungi f 682 230 25.2 <0.001
Multi-drug (MDR) resistance groups (N = 6065) MDR c 779 265 25.4 <0.001
No., number; CNS, Coagulase negative staphylococci; CVC, central venous catheter; pd, patient days.
a p-values, Chi-square test or Wilcoxon rank sum test
b other than the 13 most common organisms causing PBSI: coagulase negative Staphylococci (CNS), Enterococcus spp., S. aureus, C.albicans, non-albicans-Candida spp.,
E. coli, Klebsiella spp., Enterobacter spp., P. aeruginosa, Serratia spp., Acinetobacter spp., Proteus spp., and S. maltophilia;
c MDR, Multi-drug resistance includes Methicillin resistant S.aureus, Vancomycin resistant E.faecalis and E.faecium, and multidrug resistance defined as a resistance to
at least 3 antibiotic groups for P.aeruginosa, Acinetobacter spp., Enterobacter spp., E.coli, S.maltophilia, Klebsiella spp. and/or the resistance mechanisms ESBL for
Klebsiella pneumonia and E.coli, MDR compared to Non-MDR, includes Vancomycin sensible Enterococcus spp., Methicillin sensible S. aureus and non-multi-drug
resistance for E. coli, Klebsiella spp., Enterobacter spp., P. aeruginosa, Acinetobacter spp., S. maltophilia
d includes coagulase negative Staphylococci (CNS), Enterococcus spp., S. aureus;
e includes E. coli, Klebsiella spp., Enterobacter spp., P. aeruginosa, Serratia spp., Acinetobacter spp., Proteus spp., and S. maltophilia;
f C. albicans, non-albicans-Candida spp.
g device present <48h before diagnosis of infection
h other than Medical-surgical, Surgical, Medical, Cardiothoracic, Neurosurgical, Neurological or Pediatric.
https://doi.org/10.1371/journal.pone.0194210.t002
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ICU mortality compared to S.aureus, CNS were associated with significant lower ICU
mortality.
The significantly higher ICU mortality rates following PBSI with E.coli and Enterococci
have not been previously described and seem to be particularly interesting. Only a recent article
by Ong et al. also associated enterococci PBSI with significantly higher mortality rates [7].
These authors used data from two ICUs in the Netherlands, considered ICU discharge and
Fig 2. ICU mortality in patients with ICU-acquired primary bloodstream infection according to the type and
resistance of pathogen. ICU, intensive care unit; MDR, Multi-drug resistance includes Methicillin resistant S.aureus,
Vancomycin resistant E.faecalis and E.faecium, and multidrug resistance defined as a resistance to at least 3 antibiotic
groups for P.aeruginosa, Acinetobacter spp., Enterobacter spp., E.coli, S.maltophilia, Klebsiella spp. and/or the resistance
mechanisms ESBL for Klebsiella spp. and E.coli; Non-MDR, includes Vancomycin sensible Enterococcus spp.,
Methicillin sensible S. aureus and non-multi-drug resistance for E. coli, Klebsiella spp., Enterobacter spp., P. aeruginosa,
Acinetobacter spp., S. maltophilia; Whiskers represent 95% confidence interval.
https://doi.org/10.1371/journal.pone.0194210.g002
Fig 1. ICU mortality in patients with ICU-acquired primary bloodstream infections according to the type of
pathogen. ICU, intensive care unit; CNS, coagulase negative staphylococci; Whiskers represent 95% confidence
interval.
https://doi.org/10.1371/journal.pone.0194210.g001
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death as competing events. The occurrence of enterococcal bacteremia (not only PBSI) was fit-
ted as a time time-dependent variable. The authors of this study argue that the high risk of
death following entercoccal bacteremia may be a marker of impending complications that carry
high risk of death in the ICU rather than being causes of death on their own. For instance, the
higher mortality in Enterococci PBSI (and also E.coli) may originate in translocation from the
digestive tract of patients in unstable hemodynamic conditions, such as during shock or the
support of ECMO. The higher mortality of E.coli cannot be explained by the percentage of
multi-drug resistant E.coli. (ICU mortality non-MDR E.coli 20.9, mortality MDR-E.coli 31.3).
Our results confirm findings from earlier studies concerning Candida spp. and P.aeruginosa
which are known for a high mortality. In the past, Candida spp. was often described as leading
to higher mortality. In an analysis of more than 6000 patients with BSI, Shorr et al. demon-
strated that fungal organisms were associated with the highest mortality [14]. In a review,
the same authors described infections caused by mixed resistant Gram-negative bacteria,
Table 3. Results of multivariable analysis for mortality in intensive care units (ICU) following mono-microbial primary bloodstream infection (PBSI) according to
type of organism and further risk factors and confounders, ICU-KISS, 2006–2015.
Parameter Category AOR 95%CI p-value
Type of organism Coagulase negative staphylococci 0.86 0.75–0.99 0.030
Enterococcus spp. 1.20 1.06–1.36 0.005
Candida albicans 1.37 1.16–1.61 <.0001
E. coli 1.24 1.02–1.49 0.029
Klebsiella spp. 0.97 0.81–1.17 0.780
Enterobacter spp. 0.93 0.74–1.18 0.556
P. aeruginosa 1.49 1.21–1.84 <.0001
non-albicans-Candida spp. 1.49 1.18–1.88 0.001
Serratia spp. 0.74 0.52–1.06 0.105
Acinetobacter spp. 1.22 0.86–1.74 0.262
Proteus spp. 0.77 0.46–1.3 0.324
S. maltophilia 1.71 1.19–2.47 0.004
S. aureus 1 = reference
Gender Male 0.92 0.86–1 0.042
Female 1 = reference
Age group 45 years 0.46 0.4–0.52 <.0001
46–55 years 0.70 0.62–0.78 <.0001
56–65 years 0.79 0.72–0.86 <.0001
>65 years 1 = reference
Type of ICU Medical 1.12 0.95–1.32 0.161
Surgical 0.89 0.77–1.02 0.101
Neurosurgical 0.44 0.27–0.72 0.001
Cardiosurgical 1.48 1.18–1.85 0.001
Neurological 0.52 0.39–0.71 <.0001
Paediatric 0.55 0.38–0.8 0.002
Other a 1.02 0.8–1.3 0.887
Interdisciplinary 1 = reference
The multivariable analysis was performed using logistic regression analysis they were based on generalized estimating equation (GEE) models which account for this
clustering effect by using an exchangeable correlation structure.
AOR, adjusted odds ratio; CI, confidence interval; ICU, intensive care unit.
a other than Medical-surgical, Surgical, Medical, Cardiothoracic, Neurosurgical, Neurological or Pediatric.
https://doi.org/10.1371/journal.pone.0194210.t003
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Fig 3. Adjusted odds ratios (AOR) for ICU mortality in patients with ICU-acquired primary bloodstream
infections according to the type of pathogen. ICU, intensive care unit; CNS, coagulase negative staphylococci;
Whiskers represent 95% confidence interval; S. aureus was set as reference.
https://doi.org/10.1371/journal.pone.0194210.g003
Table 4. Results of multivariable analysis for mortality in intensive care units (ICU) following mono-microbial primary bloodstream infection (PBSI) according to
group of organisms, ICU-KISS, 2006–2015.
Parameter Category OR 95%CI p-value
Group of organisms Gram-negative a 1.12 1.01–1.23 0.024
Fungi b 1.42 1.25–1.62 <.0001
Gram-positive c 1 = reference
Gender Male 0.92 0.85–0.99 0.036
Female 1 = reference
Age group 45 years 0.45 0.4–0.52 <.0001
46–55 years 0.70 0.62–0.78 <.0001
56–65 years 0.79 0.72–0.86 <.0001
>65 years 1 = reference
Type of ICU Medical 1.15 0.98–1.35 0.085
Surgical 0.89 0.77–1.02 0.102
Neurosurgical 0.43 0.26–0.69 0.001
Cardiosurgical 1.45 1.16–1.83 0.001
Neurological 0.52 0.39–0.7 <.0001
Paediatric 0.53 0.36–0.77 0.001
Other d 1.05 0.82–1.34 0.708
Interdisciplinary 1 = reference
The multivariable analysis was performed using logistic regression analysis they were based on generalized estimating equation (GEE) models which account for this
clustering effect by using an exchangeable correlation structure
OR, odds ratio; CI, confidence interval
Model is adjusted by age, sex and type of ICU
a includes E. coli, Klebsiella spp., Enterobacter spp., P. aeruginosa, Serratia spp., Acinetobacter spp., Proteus spp., and S. maltophilia.
b includes C. albicans, non-albicans-Candida spp.
c includes coagulase negative Staphylococci, Enterococcus spp., S. aureus;
d other than Medical-surgical, Surgical, Medical, Cardiothoracic, Neurosurgical, Neurological or Pediatric.
https://doi.org/10.1371/journal.pone.0194210.t004
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extended-spectrum beta-lactamase-producing Enterobacteriaceae, multi-drug resistant Pseu-
domonas aeruginosa, and Acinetobacter species as being generally associated with increased
mortality [1]. Lambert et al. described a very high mortality rate following P.aeruginosa PBSI
in European ICU patients [5]. A recent cohort study from North Carolina reported that P.aer-
uginosa remained significantly associated with increased mortality following BSI relative to S.
aureus and other gram-negative bacteria (Hazard ratio 1.43, p = 0.02) [15]. In another study
from US hospitals that focused on severe sepsis, anaerobes and Methicillin-resistant S.aureus
were significant predictors of mortality whereas Gram-negative bacteria had decreased mortal-
ity hazards [3].
According to a recent study with data from more than 600,000 in patients from 10 Euro-
pean hospitals, which focussed on all BSI due to S.aureus and Enterobacteriaceae and also con-
sidered competing risks, S.aureus had a greater impact on mortality than Enterobacteriacae.
However, the authors pooled the data for all Enterobacteriacae and did not focus individual
species such as E.coli [8]. In our study E.coli mortality was higher than Klebsiella spp., Entero-
bacter spp., Proteus spp. and Serratia spp..
Many authors have compared the mortality rates of the susceptible and resistant variants of
the pathogens causing infections [5, 16–19]. We also tried to show the differences between the
two groups of pathogens. But we must point out that we were not able to adjust for underlying
Table 5. Results of multivariable analysis for mortality in intensive care units (ICU) following mono-microbial primary bloodstream infection (PBSI) according to
multidrug resistance groups, ICU-KISS, 2006–2015.
Parameter Category OR 95%CI p-value
Multi-drug (MDR) resistance groups MDR a 1.36 1.21–1.52 <.0001
Non-MDR b 1 = reference
Gender Male 0.91 0.84–0.98 0.017
Female 1.00 1–1 0.000
Age group 45 years 0.46 0.4–0.52 <.0001
46–55 years 0.70 0.63–0.78 <.0001
56–65 years 0.79 0.72–0.86 <.0001
>65 years 1 = reference
Type of ICU Medical 1.15 0.98–1.35 0.097
Surgical 0.92 0.8–1.06 0.236
Neurosurgical 0.43 0.27–0.7 0.001
Cardiosurgical 1.48 1.16–1.89 0.002
Neurological 0.52 0.38–0.71 <.0001
Paediatric 0.54 0.38–0.79 0.001
Other c 1.07 0.83–1.38 0.615
Interdisciplinary 1 = reference
The multivariable analysis was performed using logistic regression analysis they were based on generalized estimating equation (GEE) models which account for this
clustering effect by using an exchangeable correlation structure
OR, odds ratio; CI, confidence interval
Model is adjusted by age, sex and type of ICU
a MDR, Multi-drug resistance includes Methicillin resistant S.aureus, Vancomycin resistant E.faecalis and E.faecium, and multidrug resistance defined as a resistance to
at least 3 antibiotic groups for P.aeruginosa, Acinetobacter spp., Enterobacter spp., E.coli, S.maltophilia, Klebsiella spp. and/or the resistance mechanisms ESBL for
Klebsiella spp. and E.coli
b Non-MDR, includes Vancomycin sensible Enterococcus spp., Methicillin sensible S. aureus and non-multi-drug resistance for E. coli, Klebsiella spp., Enterobacter spp.,
P. aeruginosa, Acinetobacter spp., S. maltophilia
c other than Medical-surgical, Surgical, Medical, Cardiothoracic, Neurosurgical, Neurological or Pediatric.
https://doi.org/10.1371/journal.pone.0194210.t005
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diseases which seem to be a very important risk factor for multi-drug resistant bacteria. Only
the time, from admission until onset of infection, could be considered, which may be a surro-
gate parameter for severity of illness. This is one of the most important limitations of our anal-
ysis. For example PBSI with S.maltophilia occur after a long stay on ICU (Median 19 days).
However, the time to BSI was not significant in the multivariable analysis.
Our analysis has further limitations. First, our analysis only represents ICU mortality fol-
lowing ICU-acquired primary BSI. No BSI within the first three days on ICU or secondary BSI
are included. Second, autopsies are very rarely performed in German ICUs, thus also preclud-
ing confirmation of a direct relationship between mortality and PBSI. Third, only mortality in
the ICU was observed, but not during subsequent hospital stays. Fourth, it is impossible to pro-
vide information about the sensitivity of recording the death of the patients, but due to the use
of web-based surveillance systems, the surveillance staff cannot complete an infection case
without entering this information. Fifth, the analysis concentrates only on mono-microbial
infections; mortality following poly-microbial infections was significantly higher. Sixthly, usu-
ally the time to event has been used to account for the risk of death, but because the time to the
event “death” was not available for infected patients, such an analysis was not possible. Finally,
the database does not include any information about the underlying diseases of the patients
and empirical antimicrobial therapy (substances and the timing of antibiotics). Therefore,
adjustment related to inappropriate initial antimicrobial therapy is impossible.
Conclusion
In summary, out data shows substantial differences in mortality in German ICUs according to
the type of pathogen. Considering the aggressive nature of the pathogens identified with signif-
icantly higher mortality rates, information on the type of pathogen is itself important for the
prognosis of patients. Therefore, taking blood cultures is important and their results should be
provided to clinicians as soon as possible.
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